Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis
- 29 June 2022
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 120, 106910
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS eraPLOS ONE, 2018
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- Genetic alterations and their clinical implications in older patients with acute myeloid leukemiaLeukemia, 2016
- Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencingLeukemia, 2015
- ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene RepressionCancer Cell, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryBlood, 2011
- Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasmsLeukemia, 2011
- Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutationsBlood, 2010
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007